Validation of the Augmentation Severity Rating Scale (ASRS): A multicentric, prospective study with levodopa on restless legs syndrome

Sleep Medicine

Volumn 8, Issue 5, 2007, Pages 455-463

  García Borreguero, Diego ^a   Kohnen, Ralf ^b   Högl, Birgit ^c   Ferini Strambi, Luigi ^d   Hadjigeorgiou, Georgios M ^e   Hornyak, Magdolna ^f   de Weerd, Al W ^g   Happe, Svenja ^h   Stiasny Kolster, Karin ⁱ   Gschliesser, Viola ^c   Egatz, Renata ^a   Cabrero, Belen ^a   Frauscher, Birgit ^c   Trenkwalder, Claudia ^h   Hening, Wayne A ^j   Allen, Richard P ^k  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^b Inst Med Res Mgmt and Biometr   (Germany)

^c UNIVERSITY OF INNSBRUCK   (Austria)

^d VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^e UNIVERSITY OF THESSALY   (Greece)

^f UNIVERSITY OF FREIBURG   (Germany)

^g STICHTING EPILEPSIE INSTELLINGEN NEDERLAND SEIN   (Netherlands)

^h UNIVERSITY OF GÖTTINGEN   (Germany)

ⁱ PHILIPPS UNIVERSITY MARBURG   (Germany)

^j ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^k JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Augmentation; Clinical study; Diagnosis; Levodopa (l Dopa); Rating scale; Restless legs syndrome (RLS)

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENSERAZIDE PLUS LEVODOPA; BENZODIAZEPINE DERIVATIVE; DOPAMINE RECEPTOR STIMULATING AGENT; HYPNOTIC AGENT; LEVODOPA;

ADULT; AGED; ARTICLE; AUGMENTATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CRONBACH ALPHA COEFFICIENT; DISCRIMINANT VALIDITY; DISEASE SEVERITY; DRUG WITHDRAWAL; FEMALE; HUMAN; INTERRATER RELIABILITY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT ASSESSMENT; PRIORITY JOURNAL; RATING SCALE; RESTLESS LEGS SYNDROME; SCORING SYSTEM; SIDE EFFECT; TEST RETEST RELIABILITY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VALIDATION PROCESS;

ADULT; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; RESTLESS LEGS SYNDROME; SEVERITY OF ILLNESS INDEX; SICKNESS IMPACT PROFILE;

EID: 34250855640     PISSN: 13899457     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sleep.2007.03.023     Document Type: Article

References (20)

1. Akpinar S. Treatment of restless legs syndrome with levodopa plus benserazide. Arch Neurol 39 (1982) 739
2. Happe S., and Trenkwalder C. Role of dopamine receptor agonists in the treatment of restless legs syndrome. CNS Drugs 18 (2004) 27-36
3. Hening W.A., Allen R.P., Earley C.J., Picchietti D.L., and Silber M.H. An update on the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep 27 (2004) 560-583
4. Trenkwalder C., Garcia-Borreguero D., Montagna P., Lainey E., de Weerd A.W., Tidswell P., et al. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry 75 (2004) 92-97
5. Stiasny-Kolster K., Trenkwalder C., Fogel W., Greulich W., Hahne M., Lachenmayer L., et al. Restless legs syndrome - new insights into clinical characteristics, pathophysiology, and treatment options. J Neurol 251 Suppl. 6 (2004) VI/39-VI/43
6. Benes H., Heinrich C.R., Ueberall M.A., and Kohnen R. Long-term safety and efficacy of cabergoline for the treatment of idiopathic restless legs syndrome: results from an open-label 6-month clinical trial. Sleep 27 (2004) 674-682
7. Stiasny K., Wetter T.C., Winkelmann J., Brandenburg U., Penzel T., Rubin M., et al. Long-term effects of pergolide in the treatment of restless legs syndrome. Neurology 56 (2001) 1399-1402
8. Stiasny-Kolster K., Benes H., Peglau I., Hornyak M., Holinka B., Wessel K., et al. Effective cabergoline treatment in idiopathic restless legs syndrome. Neurology 63 (2004) 2272-2279
9. Winkelman J.W., Sethi K.D., Kushida C.A., Becker P.M., Koester J., Cappola J.J., et al. Efficacy and safety of pramipexole in restless legs syndrome. Neurology 67 (2006) 1034-1039
10. Trenkwalder C., Stiasny-Kolster K., Kupsch A., Oertel W.H., Koester J., and Reess J. Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome. Mov Disord (2006)
11. Vignatelli L., Billiard M., Clarenbach P., Garcia-Borreguero D., Kaynak D., Liesiene V., et al. EFNS guidelines on management of restless legs syndrome and periodic limb movement disorder in sleep. Eur J Neurol 13 (2006) 1049-1065
12. Allen R.P., and Earley C.J. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep 19 (1996) 205-213
13. Allen R.P., Picchietti D., Hening W.A., Trenkwalder C., Walters A.S., and Montplaisir J. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 4 (2003) 101-119
14. Garcia-Borreguero D. Augmentation: understanding a key feature of RLS. Sleep Med 5 (2004) 5-6
15. Walters A.S., LeBrocq C., Dhar A., Hening W., Rosen R., Allen R.P., et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med 4 (2003) 121-132
16. Kohnen R., Oertel W.H., Stiasny-Kolster K., Benes H., and Trenkwalder C. Severity rating of restless legs syndrome: validation of the RLS-6 scales. Sleep 27 A304 (2004) Abstract 680
17. National Institute for Mental Health. CGI. Clinical Global Impressions. In: National Institute for Mental Health, editor. Rockville, MD: 1976.
18. Trenkwalder C., Collado-Seidel V., Kazenwadel J., Wetter T., Oertel W., Selzer R., et al. One-year treatment with standard and sustained-release levodopa: appropriate long-term treatment of restless legs syndrome?. Mov Disord 18 (2003) 1184-1189
19. Sharma S. Applied multivariate techniques (1996), Wiley, New York
20. Garciá-Borreguero D, Allen RP, Kohnen R, Högl B, Trenkwalder C, Oertel W, et al on behalf of the International Restless Legs Syndrome Study Group (IRLSSG) Diagnostic Standards for Dopaminergic Augmentation of Restless Legs Syndrome: Report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group Consensus Conference at the Max Planck Institute. Sleep Med 2007; 8(5):520-30.